HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Abbott Among Firms Gaining Formula Import Approvals As Flood Closes Its Michigan Plant

As Perrigo Gains Market Share, CEO Expects Shortage To Continue Through 2022

Executive Summary

Two days before flooding closed its Sturgis plant, Abbott announced it would import 1.1m pounds of powder formula to the US from its manufacturing facility in Spain.  

You may also be interested in...



House Appropriators Reject Docking FDA FY2023 Budget Until Formula Crisis Report Provided

First-term Iowa Republican Hinson had support from Democrat as well as other GOP members for withholding part of commissioner office’s FY2023 budget. Opposition from a self-acknowledged unlikely source, committee chair DeLauro, steered votes toward rejecting the proposal.

Abbott US Nutrition Chief Testifies ‘Safety First’ During House Hearing On Formula Shortage

Abbott's s Christopher Calamari, Gerber's Scott Fitz and Reckitt Robert Cleveland didn't have ng answers about immediately solving supply shortage or about preventing another one when they testified before Oversight and Investigation Subcommittee.

Biden Mandates Prioritizing Supplies For Infant Formula Production Over All Other Uses

Democrats and Republicans vote to approve $28m emergency finding for FDA formula programs proposed in bill introduced day earlier by Democrat leaders on Appropriations Committee. Biden deems Defense Production Act applicable to manufacturing formula products.

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

RS152647

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel